Form 4: BioCryst Pharmaceuticals Director Amy McKee Receives Routine Equity Compensation

BioCryst Pharmaceuticals, Inc. director Amy McKee has received an automatic grant of Restricted Stock Units and stock options as part of the company's non-employee director compensation policy.

Summary

• Amy McKee, a Director at BioCryst Pharmaceuticals, Inc. (BCRX), was granted 12,500 shares of Common Stock in the form of Restricted Stock Units (RSUs) on June 12, 2025, with a grant price of $0.
• These RSUs are scheduled to vest on the first anniversary of the grant date, which is June 12, 2026.
• Additionally, Ms. McKee received an automatic grant of 27,181 stock options on June 12, 2025, with an exercise price of $10.40 per share.
• The stock options will become exercisable on June 12, 2026, and have an expiration date of June 12, 2035.
• Following these transactions, Ms. McKee beneficially owns 40,331 shares of Common Stock and 27,181 derivative securities (stock options).
• Both the RSU and stock option grants were made pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended.
• The filing also includes a Power of Attorney, dated June 11, 2025, granted by Amy McKee to Alane P. Barnes and Sara A. Mykrantz to prepare and file SEC reports, including Forms 3, 4, and 5.

Sentiment

Score: 7

Explanation: The filing details a routine and expected equity compensation event for a non-employee director, which is a standard practice aimed at aligning director incentives with shareholder interests. It does not contain any unexpected positive or negative financial news, thus indicating a neutral to slightly positive sentiment due to the alignment of interests.

Positives

• The automatic grant of equity compensation to a non-employee director aligns the director's financial interests with those of the shareholders, promoting long-term value creation.
• The grants are part of a pre-established compensation policy, indicating a structured and transparent approach to director remuneration.

Future Outlook

The Restricted Stock Units are set to vest on June 12, 2026, and the stock options will become exercisable on the same date, with an expiration date of June 12, 2035. These future events are contingent on the terms of the Director Compensation Policy.

Management Comments

• The Power of Attorney explicitly states that the attorneys-in-fact, Alane P. Barnes and Sara A. Mykrantz, "do not assume any of the undersigned's responsibilities to comply with the Exchange Act or any rule or regulation of the SEC."

Industry Context

The practice of compensating non-employee directors with equity, such as Restricted Stock Units and stock options, is a standard and widespread practice across publicly traded companies, particularly within the biotechnology and pharmaceutical sectors. This approach is designed to align the interests of the board members with the long-term performance and shareholder value of the company, encouraging strategic decisions that benefit equity holders.

Comparison to Industry Standards

• The compensation structure, involving automatic grants of RSUs and stock options, is consistent with common practices for non-employee director compensation in the U.S. biotech and pharmaceutical industries.
• While specific comparable companies or projects are not detailed in the filing, this type of equity-based compensation is a standard mechanism used by companies like Amgen, Gilead Sciences, and Moderna to incentivize and retain qualified independent directors, linking their remuneration directly to company performance and shareholder returns.

Corporate Governance

Related Party Transactions

• The grants of Restricted Stock Units and stock options to Amy McKee, a director of BioCryst Pharmaceuticals, Inc., constitute a related party transaction, which is disclosed as part of her compensation under the company's Non-Employee Director Compensation Policy.

Stakeholder Impact

• Shareholders: The equity grants to a director are intended to align her interests with those of the shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Management: The Power of Attorney streamlines the process for SEC filings for the director, reducing administrative burden.

Next Steps

• The Restricted Stock Units granted to Amy McKee are scheduled to vest on June 12, 2026.
• The stock options granted to Amy McKee will become exercisable on June 12, 2026.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, SEC Form 4, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, Insider Transaction, Corporate Governance